Atlas Trials

Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma

Clinical trial NCT06646588 · RECRUITING

Trial details

NCT number
NCT06646588
Sponsor
Hebei Medical University Fourth Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Neoplasms
Start date
2024-04-01
Primary completion
2026-04-30
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.